Clever Culture Systems
June 16, 2025
Company Presentation
Other
Clever Culture Systems (ASX: CC5) is an Australian biotechnology leader developing AI-powered microbiology solutions. Their flagship product, the Automated Plate Assessment System (APAS), addresses a critical global challenge in pharmaceutical manufacturing where millions of culture plates are manually processed yearly. APAS uses patent-protected machine learning and intelligent imaging to automate the interpretation and reporting of microbial growth on culture plates, supporting the sterility and compliance requirements for safe production of drugs.
Following a decade of development, Clever Culture Systems launched APAS® in 2024. Major pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, and CDMO such as Thermo Fisher Scientific have adopted APAS. With blue-chip customers in place and additional sales completed, there is a substantial market opportunity for APAS® to become the new standard in pharmaceutical microbiology automation.
Company HQ City:
Adelaide
Company HQ State:
South Australia
Company HQ Country:
Australia
Year Founded:
2004
Lead Product in Development:
APAS Independence
CEO
Brent Barnes
Year Founded
2004
Development Phase of Lead Product
Other/Not Applicable
Exchange
Australian Securities Exchange (ASX)
Ticker
CC5
When you expect your next catalyst update?
Transition to sustainable cashflow positive through accelerated product sales. Potential strategic partnerships
What is your next catalyst (value inflection) update?
2025
Website
https://www.cleverculturesystems.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}